Cipla has secured exclusive rights to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers a non-injectable alternative for managing type 1 and type 2 diabetes. Clinical trials in India demonstrated its effectiveness in reducing HbA1c levels. Cipla aims to improve diabetes management accessibility with this innovative treatment.
